AHL Partners’s Agios Pharmaceuticals AGIO Stock Holding History

AHL Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,971	Closed	-$465K	–	1243
2017 Q3	$465K	Buy	+6,971	New	+$419K	0.01%	1075

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AHL Partners's AGIO Position: Q4 2017 in Review

AHL Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2017, closing a stake of 6,971 shares — an estimated $465K sold.

AHL Partners first reported a position in AGIO in Q3 2017 and held it in 1 quarter. The position peaked at $465K in Q3 2017. 178 funds tracked by Wall St. Rank hold AGIO as of Q4 2017.

AHL Partners reported no remaining Agios Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 6,971 Agios Pharmaceuticals shares in Q4 2017, an estimated $465K.
AHL Partners first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 1 quarter.
AHL Partners's Agios Pharmaceuticals position peaked at $465K in Q3 2017.
178 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.